Navigation Links
Potential new treatment to reduce the burden of atherosclerosis in acute coronary syndrome patients

Montreal, March 15, 2011 The Montreal Heart Institute today announced the start of the Phase 2 CHI-SQUARE (Can HDL Infusions Significantly QUicken Atherosclerosis REgression?) study of CER-001 in patients with acute coronary syndrome (ACS), in collaboration with Cerenis Therapeutics, a biopharmaceutical company developing novel high-density lipoprotein (HDL) therapies to treat cardiovascular and metabolic diseases.

CER-001 is an innovative complex of recombinant human ApoA-I, the major structural protein of HDL, and phospholipids. It has been designed to mimic the structure and function of natural, nascent HDL, also known as pre-beta HDL, which is believed to be protective against atherosclerosis. It is hoped that CER-001 will further reduce cardiovascular events in high-risk patients by promoting removal of cholesterol from the vessel wall.

The double-blind, randomized, placebo-controlled, safety and efficacy study will assess the ability of CER-001 to regress coronary atherosclerotic plaque as measured by intravascular ultrasound (IVUS). The study will include over 500 patients at fifty centers in the US, Canada and Europe, and will evaluate three different dose levels given in six weekly intravenous infusions.

The study is being done in collaboration with the Global Atherothrombotic Investigative Network (GAIN). Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, is serving as the principal investigator. "We are excited to be conducting the CHI-SQUARE study, which aims to show benefits of CER-001 on atherosclerotic plaque following a short course of therapy." said Dr. Tardif. "This is the largest IVUS study conducted with a pre-beta HDL mimetic, and represents a potential new treatment paradigm to reduce the burden of atherosclerosis."

Pre-beta HDL is believed to protect against cardiovascular disease by removing cholesterol and other lipids from tissues including the arterial wall and transporting them to the liver for elimination. The aim for the clinical use of a recombinant ApoA-I HDL mimetic is to stimulate cholesterol removal in a process known as reverse lipid transport.

"Following the excellent safety and tolerability Phase I results with CER-001, this trial will evaluate the efficacy in ACS patients," said Jean-Louis Dasseux, CEO of Cerenis. "The potential of HDL therapy is well recognized and CER-001, as a first in class pre-beta HDL mimetic, could have great therapeutic value to patients with ACS."


Contact: Julie Chevrette
514-376-3330 x2641
Montreal Heart Institute

Related medicine news :

1. Marker of Ewing sarcoma: Potential new drug target?
2. Allegheny General Hospital Study Demonstrates Safety and Potential Efficacy of Oral Allergy Treatment
3. MSU researcher links potentially deadly infection, frequent cow exposure
4. Spanish Only, Please: Special Latino Clinic Launched For Potential Abdominal Transplant Patients
5. ACR, SBI: Avon Survey Reveals Potentially Deadly Effects of USPSTF Mammography Recommendations
6. Morgan & Morgan's Personal Injury Attorneys Provide Information About Yaz, Yasmin, and Ocella Injuries and Potential Health Risks
7. International Medical Corps Emergency Response Team on Standby as It Monitors Situation in Chile and Potential Tsunami Areas
8. New testing method hints at garlics cancer-fighting potential
9. Research identifies potential new use for cancer treatment
10. Midroog Ltd., an Affiliate of Moodys Investors Services, Rates Potential new Debt of Elbit Imaging
11. Innovative Service Revolutionizes How Businesses Research Product Sales Potential
Post Your Comments:
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... solution provider of IBM software products, introduced a new company, RightSensor™ LLC, an ... and data communications capability. RightSensor™ provides a fully-managed approach for customers requiring ...
(Date:10/13/2015)... ... 13, 2015 , ... Dr. Poneh Ghasri, dentist in West Hollywood , ... The research, which was conducted at the Dental Institute at King's College London in ... stress during pregnancy and future dental health in the child. For years, researchers have ...
(Date:10/13/2015)... ... October 13, 2015 , ... A child without a healthy mouth is ... the leading remote invisible aligner system, has joined with Global Dental Relief ... For each aligner treatment plan purchased, SmileCareClub will donate one clinic visit to a ...
(Date:10/13/2015)... Hills, CA (PRWEB) , ... October 13, 2015 ... ... management and workflow solutions, announced today their Title Sponsorship of Synergy 2015. The ... in Henderson, NV at Green Valley Ranch and will unite customers, partners, WennSoft ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... Illinois with more than 59,000 emergency department visits per year, today announced the ... T-System, to help improve clinical, operational and financial outcomes. , In ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... 2015  Kay Elledge, M.D., an established South ... of Obstetrics and Gynecology (FACOG) for the past ... Genuine Self Medical Laser Center where she provides ... of Breast Cancer Awareness Month , the ... MonaLisa Touch treatments initiated in the month ...
(Date:10/13/2015)... 13, 2015  Human Longevity, Inc. (HLI), the genomics-based, ... announced today the launch of the company,s first Health ... the potential to transform healthcare. The inaugural Health Nucleus ... , at HLI,s headquarters facility. More Health Nucleus facilities ... and International cities. --> ...
(Date:10/13/2015)... SAN DIEGO , Oct. 13, 2015 /PRNewswire/ ... bioelectronics for use in research and diagnostics, announces ... of $1.6 million led by Serra Ventures. ... Nanomed,s mission is providing low-cost, easy-to-use monitoring and ... personal health decisions. The funding round will enable ...
Breaking Medicine Technology: